VanEck Associates
TMCI icon

VanEck Associates’s Treace Medical Concepts TMCI Stock Holding History

VanEck Associates’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,093
Closed -$54K – 1428
2023
Q3 		$54K Buy
4,093
+1,340
+49% +$24.5K ﹤0.01% 1279
2023
Q2 		$70K Buy
2,753
+479
+21% +$12.4K ﹤0.01% 1276
2023
Q1 		$57K Hold
2,274
– – ﹤0.01% 1301
2022
Q4 		$52K Buy
+2,274
New +$52.4K ﹤0.01% 1313

Other funds holding TMCI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates's TMCI Position: Q4 2023 in Review

VanEck Associates sold out of Treace Medical Concepts (TMCI) in Q4 2023, closing a stake of 4,093 shares — an estimated $54K sold.

VanEck Associates first reported a position in TMCI in Q4 2022 and held it in 4 quarters. The position peaked at $70K in Q2 2023. 127 funds tracked by Wall St. Rank hold TMCI as of Q4 2023.

  • VanEck Associates reported no remaining Treace Medical Concepts position as of Q4 2023 after selling out during the quarter.
  • VanEck Associates sold 4,093 Treace Medical Concepts shares in Q4 2023, an estimated $54K.
  • VanEck Associates first reported a position in Treace Medical Concepts in Q4 2022 and held it in 4 quarters.
  • VanEck Associates's Treace Medical Concepts position peaked at $70K in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2023.

Based on VanEck Associates's 13F filing for Q4 2023, filed 5 Feb 2024.